Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezafungin Prophylaxis in Liver Transplant
NCT06774144Phase 3Enrolling by invitation
- Start
- Oct 2025
- Primary completion
- Dec 2028
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rezafungin in invasive fungal infection (IFI) (3 arms). Primary endpoints: Incidence of proven and probable IFIs at 90 days and Incidence of proven and probable breakthrough IFI. Started Oct 2025; status: enrolling by invitation.
02
Drugs
rezafungin
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT06774144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06774144.